Filaggrin Mutations: Evidence for Physical Barrier Defects as a Cause of AD Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI ; ISAAC Phase Three Study Group. Global variations in ...

Elaine Siegfried, MD: There’s tremendous work going on, and a lot of it is driven by investment from pharmaceutical companies in creating better treatments. Prior to very recently we had a handful of ...

The 4-part lecture, “Practical Application of Novel Targeted Strategies in Moderate-to-Severe Atopic Dermatitis” covered the pathogenesis of atopic dermatitis (AD), new insights into the ...

Scientists have identified a gene variant on chromosome 11 that is associated with an increased risk of atopic dermatitis. In a large genome-wide study the researchers scanned the genomes of more than ...

Each month, The Clinical Advisor makes one new clinical feature available ahead of print. Don’t forget to take the poll. The results will be published in the next month’s issue. Lauren Ax, MSPAS, PA-C ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...

Efficacy of the investigational drug lebrikizumab is maintained in patients with moderate to severe atopic dermatitis for at least 1 year, according to new results from the phase 3 ADvocate1 and ...

September 14 was the eighth World Atopic Dermatitis Day. Atopic dermatitis (AD) is a common, chronic, and recurrent inflammatory skin disease characterized by severe pruritus and eczematous lesions.